Predictive Oncology Inc. (POAI)
| Market Cap | 50.32M |
| Revenue (ttm) | 1.24M |
| Net Income (ttm) | -25.80M |
| Shares Out | 36.51M |
| EPS (ttm) | -1.30 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 21 |
| Last Price | $0.985 |
| Previous Close | $1.010 |
| Change ($) | -0.025 |
| Change (%) | -2.50% |
| Day's Open | 1.010 |
| Day's Range | 0.935 - 1.020 |
| Day's Volume | 1,980,269 |
| 52-Week Range | 0.630 - 2.300 |
MINNEAPOLIS, June 18, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“...
Are these Robinhood penny stocks the best to watch in 2021? The post Best Penny Stocks to Buy on Robinhood?
Looking for well-funded biotech penny stocks? Check these 3 small-caps out The post Best Biotech Penny Stocks to Buy?
MINNEAPOLIS, June 14, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“...
These four penny stocks could get a huge boost from the success of the underlying companies' AI systems going forward. The post 4 Penny Stocks With the Potential to Become Top-Notch AI Players appeared ...
MINNEAPOLIS, June 02, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discove...
MINNEAPOLIS, May 20, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), an artificial intelligence driven oncology and drug discovery company, announced today that its wholly owned subsidiary,...
MINNEAPOLIS, May 12, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (Nasdaq: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug dis...
MINNEAPOLIS, April 27, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discov...
MINNEAPOLIS, March 23, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence to personalized medicine and drug discovery, is...
MINNEAPOLIS, March 15, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) – Predictive Oncology (Nasdaq: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to ...
POAI ‘s Helomics Division Announces Progress on Milestones for its AI-Driven Model of Ovarian Cancer
Helomics Researchers Complete Key Sequencing Milestones and Focus on AI-Driven Model Building Helomics Researchers Complete Key Sequencing Milestones and Focus on AI-Driven Model Building
MINNEAPOLIS, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“...
MINNEAPOLIS, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discove...
MINNEAPOLIS, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“...
MINNEAPOLIS, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“...
MINNEAPOLIS, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discove...
MINNEAPOLIS, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“...
MINNEAPOLIS, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“...
MINNEAPOLIS, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“...
MINNEAPOLIS, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“...
EAGAN, Minn., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discov...
MINNEAPOLIS, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“...
MINNEAPOLIS, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“...
Our new PeDAL fee-for-service offering for Pharmaceutical companies will significantly improve the chances of translating discoveries into the clinic Our new PeDAL fee-for-service offering for Pharmaceu...
MINNEAPOLIS, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discove...
Reincorporation Proposal Received Overwhelming Support Among Shares Voted Reincorporation Proposal Received Overwhelming Support Among Shares Voted
NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery,...
NEW YORK, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery,...
NEW YORK, Oct. 27, 2020 (GLOBE NEWSWIRE) -- via NetworkNewsAudio — Predictive Oncology Inc. (NASDA Q : POAI) today announces that its chief executive officer, Carl Schwartz, has been featured in an excl...
EAGAN, Minn., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discove...
Predictive Oncology now has a total of 96 unique Patient Derived Cells (PDCs) from Ovarian Cancer Patients. Predictive Oncology now has a total of 96 unique Patient Derived Cells (PDCs) from Ovarian Can...
EAGAN, Minn., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug dis...
EAGAN, Minn., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug disc...
EAGAN, Minn., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug disc...
LOS ANGELES, Aug. 14, 2020 (GLOBE NEWSWIRE) -- via NetworkWire — Predictive Oncology Inc. (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalize...
Increases Readiness for Commercialization with Expanded Portfolio of Solutions for Precision Medicine
Annual Meeting of Stockholders to be Held on September 3, 2020 Annual Meeting of Stockholders to be Held on September 3, 2020
Adds Industry, Business Development and Financial Expertise Adds Industry, Business Development and Financial Expertise
Acquisition Focused on Accelerating Commercialization of AI-driven Drug Discovery and Development Acquisition Focused on Accelerating Commercialization of AI-driven Drug Discovery and Development
MINNEAPOLIS, June 29, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (the “Company,” “Predictive Oncology,” “we,” “our” or “us”) (NASDAQ: POAI), a knowledge-driven company focused on applying artif...
A Top US Medical Institution Places the First Commercial Order for the Media used to grow Ovarian Cancer Cell Types that are Exceedingly Difficult to Grow and Retain the Signatures of the Patient Derive...
CancerQuest 2020 Study on Schedule for Completion in Q2 2020 CancerQuest 2020 Study on Schedule for Completion in Q2 2020
MINNEAPOLIS, June 02, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (the “Company”) a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized med...
MINNEAPOLIS, May 14, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) has, with the announced acquisition of Soluble Therapeutics and the subsequent partnership and licensing of a novel na...
MINNEAPOLIS, May 07, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (...
MINNEAPOLIS, May 06, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) has, with the announced acquisition of Soluble Therapeutics, Inc. and the subsequent partnership and licensing of a nov...
CEO Agrees to Exchange $2.1 Million Promissory Note for Newly Issued Equity, Demonstrating Confidence in Company’s Future CEO Agrees to Exchange $2.1 Million Promissory Note for Newly Issued Equity, Dem...
NEW YORK, April 22, 2020 (GLOBE NEWSWIRE) -- via NetworkNewsAudio — Predictive Oncology (NASDAQ: POAI) today announces that Company director and CEO Dr. Carl Schwartz, in an interview with NetworkNew...
About POAI
Predictive Oncology Inc. provides various healthcare products and services primarily in the United States. The company operates in three segments: Helomics, Soluble, and Skyline. The company manufactures environmentally conscious systems for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. It offers STREAMWAY System, a wall-mounted fully automated system that disposes suction fluid providing uninterrupted performance for physicians while virtually eliminating healthcare workers' expo... [Read more...]
| Industry Medical Instruments & Supplies | Founded 2002 |
| CEO Joshua Kornberg | Employees 22 |
| Stock Exchange NASDAQ | Ticker Symbol POAI |
Financial Performance
In 2020, POAI's revenue was $1.25 million, a decrease of -11.28% compared to the previous year's $1.41 million. Losses were -$25.88 million, 33.5% more than in 2019.